Nifurtimox

Brand names: Lampit · Active ingredient: Nifurtimox

In short: LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi .

Forms & strengthsLAMPIT tablets are available as 30 mg and 120 mg tablets. •30 mg, yellow, round, biconvex tablets, functionally scored on one side for the division of the tablet into equal doses and marked with ‘30’ on the other side. …
LabelBayer HealthCare Pharmaceuticals Inc.
Label updatedMar 05, 2026

What is Nifurtimox used for?

LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi

.

Nifurtimox dosage

•LAMPIT (30 mg and 120 mg) tablets are for oral use and must be taken with food.

•LAMPIT tablets are dosed by body weight of the patient .

•LAMPIT (30 mg and 120 mg) tablets are functionally scored tablets which can be split into one-half (15 mg and 60 mg respectively) at the scored lines by hand. Do not break LAMPIT tablets mechanically with a tablet splitting device .

•LAMPIT 30 mg and 120 mg tablets can be made into a slurry as an alternative method of administration for patients who cannot swallow the tablets .

•Discontinue consumption of alcohol during treatment with LAMPIT .

•Complete the full course of treatment to prevent recurrence of the infection.

•If a dose is missed, take the missed dose as soon as possible together with food. However, if it is within 3 hours of the next scheduled dose, skip the missed dose and continue treatment as prescribed. Do not take a double dose to make up for a missed dose.

•Administer LAMPIT (30 mg and 120 mg) tablets orally three times a day with food.

•Total daily recommended dosages of LAMPIT are based on the body weight of the patient .

•Adjust LAMPIT dosage accordingly if body weight decreases during treatment .

•The recommended duration of treatment with LAMPIT is 60 days.

Table 1: Total Daily Recommended Dosages of LAMPIT Based on Body Weight

Age | Body weight group | Total daily dose of nifurtimox (mg/kg)

Birtha to less than 18 years | 41 kg or greater | 8 to 10

Less than 41 kg | 10 to 20

aTerm newborn with body weight of greater than or equal to 2.5 kg

Table 2: Individual Dosages Based on Body Weight in Pediatric Patients (Birtha to Less than 18 years of age)

Body weight (kg) | Dose (mg) | Number of LAMPIT 30 mg tablets per dose

(3 x Daily) | Number of LAMPIT

120 mg tablets per dose

(3 x Daily)

2.5 kg to 4.5 kg | 15 mg | ½ tablet | —

4.6 kg to less than 9 kg | 30 mg | 1 tablet | —

9 kg to less than 13 kg | 45 mg | 1 ½ tablets | —

13 kg to less than 18 kg | 60 mg | 2 tablets | ½ tablet

18 kg to less than 22 kg | 75 mg | 2 ½ tablets | —

22 kg to less than 27 kg | 90 mg | 3 tablets | —

27 kg to less than 35 kg | 120 mg | 4 tablets | 1 tablet

35 kg to less than 41 kg | 180 mg | — | 1 ½ tablets

41 kg to less than 51 kg | 120 mg | — | 1 tablet

51 kg to less than 71 kg | 180 mg | — | 1 ½ tablets

71 kg to less than 91 kg | 240 mg | — | 2 tablets

91 kg or greater | 300 mg | — | 2 ½ tablets

aTerm newborn with body weight of greater than or equal to 2.5 kg

Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with LAMPIT .

Do not break LAMPIT tablets mechanically with a tablet splitting device. A functional score line is used to divide the tablet by hand as follows:

•To split LAMPIT tablet, place the tablet on a flat surface with the score line facing up. …

How to take Nifurtimox — instructions & advice from the label

Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Embryo Fetal Toxicity

•Advise pregnant women and females of reproductive potential of the potential risk of LAMPIT to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.2), Use in Specific Populations (8.1, 8.3) and Nonclinical Toxicology (13.1)].

•Advise females of reproductive potential to use effective contraception while taking LAMPIT and for 6 months after the last dose .

•Advise male patients with female partners of reproductive potential to use condoms during treatment with LAMPIT and for 3 months after the final dose of LAMPIT .

Lactation

Advise nursing mothers to monitor infants exposed to LAMPIT through breast milk for vomiting, rash, decreased appetite, fever, and irritability [Use in Specific Populations (8.2)].

Infertility

Advise males of reproductive potential that LAMPIT may impair fertility . …

Warnings & precautions

Do not take this medicine if: LAMPIT tablets are contraindicated in:

•Patients with known hypersensitivity to nifurtimox or any of the excipients in LAMPIT .

•Patients who consume alcohol during treatment

Genotoxicity of LAMPIT has been demonstrated in humans, in vitro in several bacterial species and mammalian cell systems, and in vivo in rodents .

A study evaluating the cytogenetic effect of nifurtimox in pediatric patients ranging from 7 months to 14 years of age with Chagas disease demonstrated a 13-fold increase in chromosomal aberrations.

Carcinogenicity has been observed in mice and rats treated chronically with nitrofuran agents which are structurally similar to nifurtimox. Similar data have not been reported for LAMPIT . It is not known whether LAMPIT is associated with carcinogenicity in humans.

Based on findings from animal studies, LAMPIT can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, nifurtimox administered orally to pregnant rats, and rabbits during organogenesis was associated with reduced maternal body weights in rats, and abortions, fetal death, and smaller litter sizes in rabbits at doses approximately equivalent to and 2-times, respectively, the maximum recommended human dose (MRHD) of 10 mg/kg/day. Fetal malformations were observed in pregnant rabbits administered nifurtimox doses less than the MRHD .

Advise pregnant women of the potential risk to a fetus. Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with LAMPIT . Advise females of reproductive potential to use effective contraception during treatment with LAMPIT and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use condoms during treatment and for 3 months after the last dose of LAMPIT . …

Nifurtimox side effects

The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling:

•Potential for Genotoxicity, Carcinogenicity, and Mutagenicity

•Worsening of Neurological and Psychiatric Conditions

•Hypersensitivity

•Decreased Appetite and Weight Loss

•Porphyria

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflect exposure to LAMPIT in one prospective, randomized, double-blind trial (Trial 1). 330 pediatric patients with serologic evidence of T. cruzi infection and without Chagas disease-related cardiac or gastrointestinal symptoms were randomly assigned in a 2:1 fashion to a 60-day (n=219) or a 30-day (n=111) LAMPIT treatment regimen and were followed up for one year after end of treatment. LAMPIT was administered three times a day with food using a body weight-based dosing. The median treatment duration was 61 days for subjects in the 60-day regimen. The majority (86.7%) of the study population was ≥2 to <18 years of age at randomization.

Discontinuation of LAMPIT due to adverse reactions occurred in 14 of 330 (4.2%) patients overall, 12 of 219 (5.5%) patients in the 60-day arm, and 2 of 111 (1.8%) patients in the 30-day arm. Adverse reactions were reported for 213 of 330 (64.5%) patients. …

Drug interactions

Concomitant use of LAMPIT with alcohol may increase the incidence and severity of undesirable effects similar to other nitrofurans and nitroheterocyclic compounds. LAMPIT is contraindicated in patients who consume alcohol during treatment .

About this medicine

LAMPIT contains nifurtimox, an antiprotozoal. The chemical name is (E)-N-(3-Methyl-1,1-dioxidothiomorpholin-4-yl)-1-(5-nitro-2-furyl)methanimine.

The molecular weight is 287.29 and the molecular formula is C10 H13 N3 O5 S. The structural formula is:

LAMPIT (nifurtimox) tablets are yellow round, biconvex tablets, each containing 30 mg or 120 mg of nifurtimox, intended for oral use. The 30 mg tablets are functionally scored on one side and marked with ‘30’ on the other side. The 120 mg tablets are functionally scored on one side and marked with ‘120’ on the other side.

The inactive ingredients of the tablets are as follows: calcium hydrogen phosphate dihydrate, magnesium stearate, maize starch, silica colloidal anhydrous and sodium lauryl sulfate.

How it works: Nifurtimox is an antiprotozoal drug . Nifurtimox exposure-response relationships and the time course of pharmacodynamics response are unknown. At the recommended dose, nifurtimox treatment does not result in large mean increases (>20 ms) in the QTc interval.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 90d09714-a8b1-4696-8ada-f99dc54d0721. Read the full official label on DailyMed.